Actualización en el tratamiento de la colitis ulcerosa

[1]  D. Hommes,et al.  Thiopurine metabolite measurements during pregnancy in mother and child , 2009 .

[2]  R. Baldassano,et al.  Effect of a Probiotic Preparation (VSL#3) on Induction and Maintenance of Remission in Children With Ulcerative Colitis , 2009, The American Journal of Gastroenterology.

[3]  M. Stolte,et al.  Oral budesonide for maintenance treatment of collagenous colitis: a randomized, double-blind, placebo-controlled trial. , 2008, Gastroenterology.

[4]  L. A. Christensen,et al.  Long-term budesonide treatment of collagenous colitis: a randomised, double-blind, placebo-controlled trial , 2008, Gut.

[5]  K. Papadakis,et al.  Thiopurine methyltransferase activity combined with 6-thioguanine metabolite levels predicts clinical response to thiopurines in patients with inflammatory bowel disease. , 2008, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[6]  M. Kamm,et al.  MMX mesalazine for the induction of remission of mild‐to‐moderately active ulcerative colitis: efficacy and tolerability in specific patient subpopulations , 2008, Alimentary pharmacology & therapeutics.

[7]  D. Margolis,et al.  Immunosuppressant Medications and Mortality in Inflammatory Bowel Disease , 2008, The American Journal of Gastroenterology.

[8]  C. Mulder,et al.  503 Alteration of Thiopurinephosphate Metabolite Levels By Aminosalicylates in IBD-Patients , 2008 .

[9]  A. Sood,et al.  701 A Randomized, Double-Blind, Placebo-Controlled Trial of a Probiotic Preparation, Vsl#3, for the Treatment of Mild to Moderate Active Ulcerative Colitis , 2008 .

[10]  M. Stolte,et al.  T1123 Oral Budesonide for Maintenance Treatment of Collagenous Colitis: A Randomised, Placebo-Controlled, Double-Blind Trial , 2008 .

[11]  A. Gasbarrini,et al.  S1245 Mucosal Healing in Ulcerative Colitis Patients in Long-Term Therapy with Infliximab , 2008 .

[12]  D. Hommes,et al.  502 Thiopurine Metabolite Measurements During Pregnancy in Mother and Child , 2008 .

[13]  M. Setshedi,et al.  947 Risk of Malignancy in Patients with Inflammatory Bowel Disease Treated with Azathioprine or 6-Mercaptopurine: the Cape Town Experience , 2008 .

[14]  F. Autschbach,et al.  706 Retarded Release Phosphatidylcholine in Non-Steroid-Treated Ulcerative Pancolitis: A Randomized, Controlled Dose Finding Study , 2008 .

[15]  P. Rutgeerts,et al.  946 Corticosteroids Pose An Increased Risk for Serious Infection: An Interim Safety Analysis of the ENCORE Registry , 2008 .

[16]  S. Hanauer,et al.  1041 Intravenous Cyclosporin in Severe Steroid-Refractory Ulcerative Colitis: Long-Term Follow-Up , 2008 .

[17]  H. Drummond,et al.  1043 The Efficacy of Corticosteroid Therapy: Analysis of 10-Year Inflammatory Bowel Disease Inception Cohort (1998-2007) , 2008 .

[18]  A. Lorenzo,et al.  W1262 Prospective, Open Pilot Study for Evaluating the Clinical Efficacy and Mucosal Healing Rate of Infliximab in Steroid-Dependent Ulcerative Colitis , 2008 .

[19]  P. Rutgeerts,et al.  T1153 Infliximab Treatment for Ulcerative Colitis: Comparable Clinical Response, Clinical Remission, and Mucosal Healing in Patients with Disease Duration < 3 Years Vs ≥ 3 Years , 2008 .

[20]  P. Rutgeerts,et al.  T1142 Infliximab Treatment for Ulcerative Colitis: Clinical Response, Clinical Remission, & Mucosal Healing in Patients with Moderate or Severe Disease in the Active Ulcerative Colitis Trials (ACT1 & ACT2) , 2008 .

[21]  Z. Farajzadegan,et al.  705 New Insights of Anti-Depressant Therapy in the Management of Ulcerative Colitis (UC) , 2008 .

[22]  R. Baldassano,et al.  1013 Effect of a Probiotic Preparation (VSL #3) On Induction and Manteinance of Remission in Children with Ulcerative Colitis , 2008 .

[23]  D. Margolis,et al.  969 Immunosuppressant Medications and Mortality in Inflammatory Bowel Disease , 2008 .

[24]  J. Hugot,et al.  818 Excess Risk of Lymphoproliferative Disorders (LPD) in Inflammatory Bowel Diseases (IBD): Interim Results of the Cesame Cohort , 2008 .

[25]  A. Lavy,et al.  T1137 A Novel High Dose 1g Mesalamine Suppository (Salofalk®) Is As Efficacious As 500mg TID Suppositories in Mild to Moderate Active Ulcerative Proctitis: A Multicenter, Randomized Trial , 2008 .

[26]  P. Rutgeerts,et al.  T1139 The ACT Trials: Incremental Benefit of Second and Third Induction Doses of Infliximab in Patients with Moderately-to-Severely Active Ulcerative Colitis (UC) , 2008 .

[27]  R. Mueller,et al.  T1124 Once Daily 3g Mesalamine Is the Optimal Dose for Maintaining Clinical Remission in Ulcerative Colitis: A Double-Blind, Double-Dummy, Randomized, Controlled, Dose-Ranging Study , 2008 .

[28]  J. Reguła,et al.  702 Efficacy and Safety of Delayed-Release Oral mesalamine At 4.8g/D (800mg Tablet) in the Treatment of Moderately Active Ulcerative Colitis: Results of the Ascend III Study , 2008 .

[29]  W. Bemelman,et al.  European Evidence-based Consensus on the Management of Ulcerative Colitis: Current Management , 2007 .

[30]  G. Damonte,et al.  820 Erythrocytes-Mediated Delivery of Low Doses of Dexamethasone Revert Steroid-Dependency in Ulcerative Colitis. a Double-Blind, Sham-Controlled Study , 2008 .

[31]  J. Gisbert.  S1251 6-Thioguanine Nucleotide (6-TGN) Concentrations and Efficacy of Azathioprine (AZA) and Mercaptopurine (MP) in Inflammatory Bowel Disease: the Metaza Study , 2008 .

[32]  Y. González-Lama.  S1250 Utility of Azathioprine Metabolites Determination During Follow Up of Inflammatory Bowel Disease Patients After Steroid Treatment Withdrawal , 2008 .

[33]  V. Armstrong,et al.  6-thioguanine nucleotide-adapted azathioprine therapy does not lead to higher remission rates than standard therapy in chronic active crohn disease: results from a randomized, controlled, open trial. , 2007, Clinical chemistry.

[34]  M. Kamm,et al.  MMX Multi Matrix System® mesalazine for the induction of remission in patients with mild‐to‐moderate ulcerative colitis: a combined analysis of two randomized, double‐blind, placebo‐controlled trials , 2007, Alimentary pharmacology & therapeutics.

[35]  S. Hanauer,et al.  Delayed-release oral mesalamine 4.8 g/day (800 mg tablets) compared to 2.4 g/day (400 mg tablets) for the treatment of mildly to moderately active ulcerative colitis: The ASCEND I trial. , 2007, Canadian journal of gastroenterology = Journal canadien de gastroenterologie.

[36]  W. Sandborn,et al.  Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry. , 2006, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[37]  W. Tremaine,et al.  American Gastroenterological Association Institute medical position statement on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease. , 2006, Gastroenterology.

[38]  Paul Rutgeerts,et al.  Infliximab for induction and maintenance therapy for ulcerative colitis. , 2005, The New England journal of medicine.

[39]  F. Ajayi,et al.  Delayed-Release Oral Mesalamine at 4.8 g/day (800 mg tablet) for the Treatment of Moderately Active Ulcerative Colitis: The ASCEND II Trial , 2005, The American Journal of Gastroenterology.

[40]  P. Rutgeerts,et al.  The limitations of corticosteroid therapy in Crohn’s disease , 2001, Alimentary pharmacology & therapeutics.

[41]  S. Hanauer,et al.  Prevalence of nonadherence with maintenance mesalamine in quiescent ulcerative colitis , 2001, American Journal of Gastroenterology.

[42]  A. Zinsmeister,et al.  The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. , 2001, Gastroenterology.

[43]  P. Munkholm,et al.  Frequency of glucocorticoid resistance and dependency in Crohn's disease. , 1994, Gut.